- SURMOUNT-MAINTAIN (NCT06047548), a 112-week Phase 3b trial, showed Zepbound MTD preserved prior weight loss at week 112 while reducing to 5 mg retained all but 5.6 kg on average.
- ATTAIN-MAINTAIN (NCT06584916), two 52-week Phase 3b cohorts, found switching from Wegovy MTD to Foundayo kept all but 0.9 kg at 52 weeks and switching from Zepbound MTD to Foundayo kept all but 5.0 kg.
- Drugs studied: Zepbound (tirzepatide) once-weekly dual GIP/GLP-1, Foundayo (orforglipron) once-daily oral GLP-1, and Wegovy (semaglutide) injectable.
- Safety profiles for Foundayo and Zepbound were consistent with prior Phase 3 studies.
SURMOUNT-MAINTAIN results
SURMOUNT-MAINTAIN (NCT06047548), a 112-week Phase 3b randomized, double-blind, placebo-controlled maintenance trial, showed participants who continued Zepbound at maximum tolerated dose (MTD) preserved all prior weight loss at week 112, while reducing Zepbound to 5 mg retained all but 5.6 kg on average; group averages: MTD→MTD — baseline 112.2 kg, after 60 weeks on MTD 89.5 kg, at 52 weeks maintenance 88.7 kg; MTD→5 mg — baseline 113.4 kg, after 60 weeks 89.0 kg, at 52 weeks maintenance 94.6 kg.
ATTAIN-MAINTAIN results
ATTAIN-MAINTAIN (NCT06584916), two 52-week Phase 3b cohorts of SURMOUNT-5 completers, found switching to oral Foundayo maintained most prior loss: Wegovy MTD→Foundayo retained all but 0.9 kg (start of SURMOUNT-5 113.5 kg; at switch 95.0 kg; after 52 weeks oral maintenance 95.9 kg), and Zepbound MTD→Foundayo retained all but 5.0 kg (start of SURMOUNT-5 115.8 kg; at switch 90.9 kg; after 52 weeks oral maintenance 95.9 kg).
Drugs, safety and publication
Agents studied: Zepbound (tirzepatide) once-weekly dual GIP/GLP-1, Foundayo (orforglipron) once-daily oral GLP-1, and Wegovy (semaglutide) injectable; safety profiles were consistent with prior Phase 3 studies; results were presented at the 33rd European Congress on Obesity and published in The Lancet and Nature Medicine.
